IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q4 2022
Institutional positions in IO Biotech, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- −4 vs. Q3 2022
- Shares held
- 14.3M
- −1.05M (−6.9%) vs. Q3 2022
- Total value
- $32.8M
- −$8.71M (−21.0%) vs. Q3 2022
- New holders
- 0
- 4 more added
- Sold out
- 4
- 5 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Novo Holdings A/S | 3,277,932 | $7.54M | 0.47% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,015,545 | $6.94M | 0.84% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 2,055,883 | $4.73M | 0.07% | 00.0% | Unchanged |
| Bank of America Corp | 1,854,185 | $4.26M | 0.00% | +1,844,185+18,441.9% | Added |
| Ra Capital Management, L.P. | 1,127,260 | $2.59M | 0.05% | −730,495−39.3% | Reduced |
| Capital World Investors | 1,071,311 | $2.46M | 0.00% | −163,689−13.3% | Reduced |
| Samsara BioCapital, LLC | 1,008,437 | $2.32M | 0.50% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 507,640 | $1.17M | 0.05% | −1,651,515−76.5% | Reduced |
| Bridgeway Capital Management, LLC | 132,200 | $304.1K | 0.01% | +36,300+37.9% | Added |
| Newtyn Management, LLC | 90,000 | $207.0K | 0.04% | −10,000−10.0% | Reduced |
| Psagot Value Holdings Ltd. / (Israel) | 40,846 | $94.0K | 0.03% | 00.0% | Unchanged |
| Morgan Stanley | 29,060 | $66.8K | 0.00% | +7,000+31.7% | Added |
| Renaissance Technologies LLC | 24,200 | $56.0K | 0.00% | +5,777+31.4% | Added |
| Millennium Management LLC | 20,554 | $47.0K | 0.00% | −17,768−46.4% | Reduced |
| Geode Capital Management, LLC | 12,730 | $29.0K | 0.00% | 00.0% | Unchanged |
| Cannell Capital LLC | 12,594 | $29.0K | 0.01% | 00.0% | Unchanged |
| Ancora Advisors, LLC | 908 | $2.00K | 0.00% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −288,119−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −43,741−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −42,180−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −28−100.0% | Sold out |